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Abstract
Background: At present, screening of the population at risk for gambiense human African trypanosomiasis (HAT) is based on
detection of antibodies against native variant surface glycoproteins (VSGs) of Trypanosoma brucei (T.b.) gambiense.
Drawbacks of these native VSGs include culture of infective T.b. gambiense trypanosomes in laboratory rodents, necessary
for production, and the exposure of non-specific epitopes that may cause cross-reactions. We therefore aimed at identifying
peptides that mimic epitopes, hence called ‘‘mimotopes,’’ specific to T.b. gambiense VSGs and that may replace the native
proteins in antibody detection tests.
Methodology/Principal Findings: A Ph.D.-12 peptide phage display library was screened with polyclonal antibodies from
patient sera, previously affinity purified on VSG LiTat 1.3 or LiTat 1.5. The peptide sequences were derived from the DNA
sequence of the selected phages and synthesised as biotinylated peptides. Respectively, eighteen and twenty different
mimotopes were identified for VSG LiTat 1.3 and LiTat 1.5, of which six and five were retained for assessment of their
diagnostic performance. Based on alignment of the peptide sequences on the original protein sequence of VSG LiTat 1.3
and 1.5, three additional peptides were synthesised. We evaluated the diagnostic performance of the synthetic peptides in
indirect ELISA with 102 sera from HAT patients and 102 endemic negative controls. All mimotopes had areas under the
curve (AUCs) of $0.85, indicating their diagnostic potential. One peptide corresponding to the VSG LiTat 1.3 protein
sequence also had an AUC of $0.85, while the peptide based on the sequence of VSG LiTat 1.5 had an AUC of only 0.79.
Conclusions/Significance: We delivered the proof of principle that mimotopes for T.b. gambiense VSGs, with diagnostic
potential, can be selected by phage display using polyclonal human antibodies.
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Introduction
The chronic form of sleeping sickness or human African
trypanosomiasis (HAT) in West and Central Africa is caused by
the protozoan parasite Trypanosoma brucei (T.b.) gambiense while T.b.
rhodesiense causes a more fulminant, acute form in East and
Southern Africa. Both subspecies of T. brucei are cyclically
transmitted by tsetse flies of the genus Glossina and mainly affect
poor, rural populations. The true burden of this disease is
unknown as many cases remain undiagnosed or unreported [1,2].
Since untreated HAT is almost always fatal and no inexpensive,
safe and easily administered drugs are available, accurate case
detection is crucial. Parasite detection is laborious and insensitive,
and remains therefore limited to disease suspects. In the absence of
reliable clinical symptoms or antigen detection tests, HAT suspects
are identified through screening of the population at risk for
presence of trypanosome specific antibodies. The commonly used
antibody detection tests, card agglutination test for trypanosomiasis
(CATT) [3], LATEX/T.b. gambiense and ELISA/T.b. gambiense [4,5]
detect antibodies against the highly immunogenic variant surface
glycoproteins (VSGs) of T.b. gambiense. Even though the genome of
T. brucei contains .1000 VSG genes, only one variable antigen type
(VAT) is expressedat a time.Stochastic switchingofVSGallows the
trypanosome to evade the specific antibody responses that were
raised against earlier VATs [6–10]. Some VATs, such as LiTat 1.3
and 1.5, are recognised by almost all gambiense HAT patients and
therefore called predominant. The dense VSG monolayer on the
living trypanosome shields all non-specific epitopes. The hypervari-
able N-terminal VSG domain (300–400 residues) is exposed to the
immune system and comprises the VAT-specific epitopes, while the
relatively conserved C-terminal domain (40–80 residues) is hidden
by the intact VSG coat [6,9,11,12].
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the occurrence of non-specific reactions. This might be explained
by exposure of non-HAT-specific epitopes that are normally
shielded on the living trypanosome [12,13]. In addition, diagnostic
test production actually requires culture of infective T.b. gambiense
in large numbers of laboratory rodents and poses an important risk
of infection to the manufacturing staff [14].
These drawbacks can be circumvented through the use of
synthetic peptides that mimic HAT-specific VSG epitopes
(mimotopes) and can be produced in a standardised way [15].
One way to identify such mimotopes is by peptide phage display.
This technique is based on DNA recombination resulting in
foreign peptides with random sequences that are displayed fused to
the pIII surface protein of the M13 phage. After an in vitro selection
process based on binding affinity and several rounds of enrichment
(panning), the encoded peptide insert sequence of the selected
phage is deduced from the phage DNA. We previously reported
successful identification of mimotopes for VSG LiTat 1.3 and
LiTat 1.5 by performing phage display with three monoclonal
antibodies [16]. However, by the use of only three monoclonal
antibodies, representing only a fraction of the VSG-specific
antibody response, some mimotopes with diagnostic potential
might have been missed. Additionally, the mouse and human
immune system may recognise different B cell epitopes. The use of
polyclonal human antibodies might therefore increase chances of
selecting diagnostic mimotopes [17]. Polyclonal antibodies from
human sera have been previously used for selection of mimotopes
with diagnostic potential for e.g. hepatitis C [15], typhoid fever
[18] and Epstein Barr virus [17]. Some mimotopes have been
patented for incorporation in commercially available tests, e.g. for
neurocysticercosis [19].
In this manuscript we describe the identification of mimotopes
for VSG LiTat 1.3 and LiTat 1.5 through phage display, using
sera from HAT patients and endemic negative persons.
Materials and Methods
Ethics statement
Sera from HAT patients and endemic controls were collected
within different diagnostic studies [5,20]. All individuals gave their
written informed consent before providing blood. Permission for
these studies was obtained from the national ethical committee of
the Democratic Republic of the Congo (DR Congo) and from the
Institute of Tropical Medicine Antwerp (ITMA) ethical commit-
tee, reference number 03 07 1 413 and 04 44 1 472. Forty
additional endemic negative control specimens were obtained
from the archived specimen bank of the Parasite Diagnostics Unit
at ITMA. All specimens were anonymised.
Coating of magnetic particles with VSG LiTat 1.3 or LiTat
1.5
Variant surface glycoproteins were purified from cloned popu-
lations of T.b. gambiense Variable Antigen Type (VAT) LiTat 1.3 and
1.5 [4]. VSG LiTat 1.3 or LiTat 1.5 were coated onto magnetic
particles (MP, Estapor, 10% suspension, 1.04 mm, 9 meq/g
COOH). A volume of 250 mL of MP suspension was washed twice
with 1 mL of buffer A (10 mmol/L NaH2PO4, pH 6.0). The MP
were activated with 2.5 ml of buffer A containing 25 mg of 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide (Pierce) and 15 mg of N-
hydroxysuccinimide (Sigma). The MP were rotated for 15 minutes
at room temperature (rT) and washed with 1 mL of buffer B
(2 mmol/L HCl) where after 350 mg of VSG (LiTat 1.3 or LiTat
1.5) in 1.5 mL of buffer C (20 mmol/L NaH2PO4/Na2HPO4,
pH 7.5) was added to the pellet of MP. After rotating for 2 h at rT,
theMP were washedthreetimes with buffer C and resuspended to a
final concentration of 8% in buffer C containing 100 mmol/L
glycin,1%bovineserumalbumin(BSA)and 0.1%NaN3.Successful
coating of the MP was evaluated by agglutination with a HAT
positive serum diluted 1/4 in phosphate buffered saline (PBS,
0.01 mol/L phosphate, 0.14 mol/L NaCl, pH 7.4) containing
0.02% w/v NaN3.
Affinity purification of VSG LiTat 1.3 or LiTat 1.5 specific
antibodies from HAT serum
Antibodies specific to VSG LiTat 1.3 or LiTat 1.5 were purified
from nine HAT positive sera originating from the DR Congo [20].
One mL of LiTat 1.3 or LiTat 1.5 coated MP was rotated for 2 h
at rT with 125 mL of HAT positive serum. After five washes with
800 mL of PBS, the specific antibodies were eluted from the MP by
adding 700 mL of 0.2 mol/L glycine/HCl (pH 2.2) followed by
magnetic separation after five minutes. The eluates, corresponding
to the affinity purified antibody fractions, were neutralised with
100 mL of 1 mol/L Tris/HCl pH 9.1.
Indirect ELISA on VSG
Indirect ELISA was used to screen the affinity purified antibody
fractions and all human serum samples on reactivity with VSG
LiTat 1.3 and LiTat 1.5. ELISA plates (Nunc MaxiSorp
TM) were
coated overnight (ON) at 4uC with 100 mL/well of 2 mg/mL of
each VSG separately in phosphate buffer (PB, 0.01 mol/L
phosphate, pH 6.5) or with 1.7 10
11 particle/mL of wild type
phage (WTP) in PBS. One plate was left empty as antigen negative
control (Ag0). The plates were tapped dry, saturated with 350 mL/
well of PBS-Blotto (0.01 mol/L phosphate, 0.2 mol/L NaCl, 1%
w/v skimmed milk powder, 0.05% w/v NaN3) during 1 h at rT
and washed three times with 0.05% v/v Tween-20 in PBS (PBST)
(ELx50, Bio-Tek ELISA washer). The purified antibody fractions
were diluted 1/25 and human serum samples 1/150 in PBS-
Blotto. One hundred mL/well of each dilution was applied in
duplicate and incubated for 1 h at rT. After three washes with
PBST 100 mL/well of horse radish peroxidase (PO)-conjugated
goat anti-human IgG (H+L) (Jackson), 1/40000 diluted in PBST,
was added. An hour and five washes later, wells were incubated for
1 h at rT with 100 mL/well of 2.29-azino-bis-(3-ethylbenzthiazo-
line-6-sulfonic acid) (ABTS) chromogen/substrate solution (50 mg
tablet/100 mL of ABTS buffer, Roche). The plate was shaken for
ten seconds and the optical density (OD) was read at 414 nm
(Labsystems Multiskan RC 351). The measured OD was corrected
(ODc) with the corresponding OD in the Ag0 wells.
Author Summary
Control of the chronic form of sleeping sickness or
gambiense human African trypanosomiasis (HAT) consists
of accurate diagnosis followed by treatment. We aim to
replace the native variant surface glycoprotein (VSG)
parasite antigens that are presently used in most antibody
detection tests with peptides that can be synthesised in
vitro. Antibodies recognising VSG were purified from HAT
patient sera and were used to select phage-expressed
peptides that mimic VSG epitopes from a Ph.D.-12 phage
display library. The diagnostic potential of the correspond-
ing synthetic peptides was demonstrated in indirect ELISA
with sera from HAT patients and endemic negative
controls. We proved that diagnostic mimotopes for T.b.
gambiense VSGs can be selected by phage display
technology, using polyclonal human antibodies.
Peptide Mimotopes for T.b.gambiense VSG
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Three LiTat 1.3 positive pools, each consisting of three different
VSG LiTat 1.3-specific antibody fractions, three LiTat 1.5 positive
pools, each consisting of three different VSG LiTat 1.5-specific
antibody fractions and one negative pool of four endemic negative
sera were prepared. For each pool the antibodies were coated onto
anti-human IgG (H+L) functionalised magnetic particles (MP) (1%
w/v, 1.05 mm, Estapor/Merck) according to the guidelines of the
manufacturer.
Selection of mimotopes for VSG LiTat 1.3 and LiTat 1.5 by
panning of phage-displayed peptides
The panning was performed with the Ph.D.-12 (12-mer) phage
display library (New England Biolabs, NEB) [21] through two
rounds consisting of 1) a positive selection with anti-VSG (LiTat
1.3 or 1.5, respectively) antibodies coated on MP, 2) a negative
selection with endemic negative serum antibodies coated on MP
and 3) phage amplification [22]. Each positive selection was
followed by phage titration and sandwich ELISA. After these two
rounds a third positive selection was performed.
Positive selection
Positive selection was performed as previously described [16].
Bound phages were eluted for ten minutes with 600 mLo f
0.2 mol/L glycine-HCl containing 1 mg/mL BSA (pH 2.2) and
neutralised with 90 mL of Tris-HCl (1 mol/L, pH 9.1).
Negative selection
Six hundred mL of the elution from the positive selection was
rotated ON at 4uC with 1 mg of MP coated with endemic negative
serum antibodies, in a total volume of 1 mL of PBSG.
Amplification and purification of phages
The unbound phages in 900 mL of the supernatant of the
negative selection were amplified, in a culture of Escherichia (E.) coli
(strain ER2738, NEB) at early log (0.01–0.05 A600), and purified
with PEG-NaCl as previously described [16,21].
Titering of phages
Phages from the first, second and third positive selection were
diluted in PBS 10
1 to 10
4,1 0
2 to 10
5,1 0
4 to 10
7, respectively. Ten
mL of these dilutions were incubated for five minutes with 200 mL
of an E. coli culture in mid-log (0.4–0.5 A600). The mixture was
then pipetted into 4 mL of Top-Agar (50uC) and poured onto agar
plates containing 1 mL/L IPTG/X-gal (1.25 g isopropyl b-D-
thiogalactoside, 1 g 5-bromo-4-chloro-3-indolyl-b-D-galactoside,
25 mL dimethylformamide); ninety-four blue clones were picked
and each clone was inoculated in 200 mL of lysogeny broth (LB) in
a sterile culture plate (BD Falcon
TM Clear 96-well Microtest
TM
Plate) [21]. This plate was shaken overnight at 30uC, and then the
bacteria were pelleted by 5 min centrifugation at 1312 g. The
supernatant was tested in a sandwich ELISA.
Sandwich ELISA with phage particles
ELISA plates were coated ON at 4uC with 100 mL/well of VSG
LiTat 1.3- or LiTat 1.5-specific positive antibody pools (5 mg/mL
in PBS) or a 1/10000 dilution in PBS of the negative serum pool.
The ELISA was performed as previously described [16]. Briefly,
the wells were incubated for 1 h at rT with 100 mL of phage
dilution in PBS-Blotto (1/3 for culture plate supernatant or 1/20
for PEG-NaCl purified phage). PO-anti-M13 pVIII mAb (GE
Healthcare), diluted 1/2000 in PBST was added to the wells for
1 h at rT. The wells were then incubated for 1 h at rT with ABTS
and read at 414 nm.
Phage clones were withheld after the first two positive selections
if 1) the OD with the corresponding positive pool (ODpos).aver-
age ODpos+2*standard deviation (sdpos) and 2) the OD with the
negative pool (ODneg),average ODneg.
After the third positive selection, phages were sequenced if 1)
ODpos.average ODpos+1* sdpos with at least one of the positive
pools,2)ODposwiththe 3
rdpositive pool .0.150or0.200forphages
selected for VSG LiTat 1.3 or LiTat 1.5 respectively and 3)
ODneg,average ODneg.Withheldphageclonesweresequencedand
testedina similarsandwichELISAwith ascaptureantibodythe nine
individual affinity purified antibody fractions, diluted 1/70 in PBS.
Single-stranded DNA extraction, sequencing and
sequence analysis
Purification of phage DNA was performed according to the NEB
manual [21]. Sequence determination was performed as described
before [16]. The obtained sequence chromatograms were read with
Chromas 2.33 (Technelysium Pty Ltd). Sequence alignment was
performed manually and with RELIC software [23]. A protein data
base (pdb) model of the N-terminal domain of VSG LiTat 1.5, was
created using SWISS-MODEL [24,25]. Modelling was based on the
known structure of VSG MITat 1.2 (pdb 1vsgA), previously derived
by X-ray crystallography [26]. For VSG LiTat 1.3 however the server
could not find a template with sufficient sequence homology, hence
the pdb was created by Thomas Juetteman from the PyMol helpdesk
(PyMOL Molecular Graphics System, Schro ¨dinger, LLC). In order to
identify possible conformational epitopes, the 3D-Epitope-Explorer
(3DEX) [27] was used to find structural homology between the
mimotope sequences and the respective VSG protein sequence.
Molecular graphics images were produced using the UCSF
Chimera package from the Resource for Biocomputing, Visual-
ization, and Informatics at the University of California, San
Francisco (supported by NIH P41 RR001081) (http://www.cgl.
ucsf.edu/chimera).
Peptide synthesis
The peptides were synthesised at .85% purity (Peptide 2.0,
Chantilly, VA, U.S.). The GGGS-spacer, separating the library
insert and the pIII phage protein, was added to the C-terminus of
the peptides that were selected by phage display [16,21]. All
peptides were C-terminally elongated with an additional lysine-
biotin and amidated (-CONH2), mimicking the uncharged peptide
bond in a protein. All synthetic peptides were reconstituted in
sterile deionised H2O to a concentration of 2 mg/mL.
Indirect ELISA on biotinylated synthetic peptides and
human sera
First, the reactivity of all biotinylated synthetic peptides was
evaluated with the nine sera used for affinity antibody purification
and nine endemic negative controls. Second, the diagnostic
performance of the synthetic peptides was evaluated with human
serum samples that were previously screened (indirect ELISA on
VSG, serum dilution 1/100) on reactivity with VSG LiTat 1.3 and
1.5. All 102 serum samples from gambiense HAT patients originated
from DR Congo [20]. Of the 102 endemic gambiense HAT negative
serum samples, 71 originated from the DR Congo and 31 from
Benin. The indirect ELISA on biotinylated peptides was performed
as the indirect ELISA on VSG but 150 mL/well was applied in all
but the saturation and washing steps. ELISA plates were coated
with 10 mg/mL streptavidin (NEB) in carbonate buffer (0.1 mol/L,
pH 9.2) or with 2 mg/mL VSG LiTat 1.3 and LiTat 1.5 in PB, or
Peptide Mimotopes for T.b.gambiense VSG
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peptides were added at a concentration of 2 mg/mL in PBS to the
wells containing streptavidin. The peptide-free wells received only
PBS. To the VSG-containing and Ag0 wells PBS-5% w/v sucrose
was added. After incubation of 1 h at rT the plates were tapped dry,
sealed and frozen at 280uC. The serum samples were centrifuged
for 5 min at 15700 g and diluted 1/100 in PBS-Blotto. After
thawing of the plates and three washes with PBST, the serum
dilutions were applied in duplicate. After one hour, we added PO-
conjugated goat anti-human IgG (H+L), 1/40000 diluted in PBST.
ABTS was used as chromogen/substrate solution and the OD was
read as described above. The measured OD was corrected by
subtracting the corresponding OD in the peptide-free or Ag0 wells
and the average of the duplicate corrected ODs was taken (ODc).
The accuracy of the synthetic peptides to detect VSG-specific
antibodies for diagnosis of sleeping sickness was assessed by the
area under the receiver operator characteristics (ROC) curve
(AUC) [28]. Confidence intervals were calculated according to
DeLong [29]. For the whole range of cut-offs the Youden index
was determined (Youden index=sensitivity+specificity21) [30]
and the cut-off with maximal Youden index was retained.
Results
Affinity purification of VSG-specific antibodies
In indirect ELISA, all affinity purified antibody fractions
reacted specifically with their corresponding VSG and not with
WTP. The antibody fractions that were purified with VSG LiTat
1.3, had an average ODc of 0.53360.319 with VSG LiTat 1.3,
and average ODcs of only 0.03260.032 with VSG LiTat 1.5 and
20.00860.015 with WTP. The antibody fractions purified with
VSG LiTat 1.5 had an average ODc of 1.40660.487 with VSG
LiTat 1.5, and average ODcs of only 0.03760.064 with VSG
LiTat 1.3 and 20.01760.018 with WTP.
The negative serum samples did not react with VSG LiTat 1.3
(ODc 0.03460.078), nor with VSG LiTat 1.5 (ODc 0.02860.069),
nor with WTP (ODc 0.01360.029).
Selection of mimotopes for VSG LiTat 1.3
During the selection process, none of 94 phage clones of the first
positive selection, eight of 188 phage clones of the second positive
selection and 11 of 188 phage clones of the third positive selection
reacted in the sandwich ELISA and were sequenced, resulting in
18 sequences (table 1).
The alignment results of VSG LiTat 1.3 [GenBank AJ304413]
and the eighteen peptide sequences displayed by the phage clones
are presented in figure 1. All peptides could be aligned within
amino acid stretch (AA) 72 to 116 of the N-terminal domain of
VSG LiTat 1.3 (alignment 1). The common motive (F/W)Ex-
DxK(A/V/L)x(A/V/L) was repeated twice in this VSG AA
stretch. Therefore twelve sequences could be aligned twice within
this region. The peptide displayed by phage 3-3-F6,
ETDNMKPLHLRQ, could even be aligned three times within
this region of VSG LiTat 1.3, having ETD, DNxKP and ExD
identical within amino acids 78 to 80, 87 to 91 and 102 to 104 of
theproteinsequence.Thepeptidesequencedisplayedbyphage3-2-
Table 1. Peptide sequences of phage clones selected with human anti-VSG LiTat 1.3 antibodies.
Pos selection Phage clone Peptide sequence ODc (average ± SD) Synthetic peptide
2 3-2-E2 WDSDCKRSCRVH 0.75560.924 3-2-E2
2 3-2-G5 LTWVSDSKSGNT 0.53060.528 3-2-G5
2 3-2-G10 TIAPSWATDSKP 0.44960.417 3-2-G10
2 3-2-C5 TPNNAQKQPQLP 0.44460.533 3-2-C5
2 3-2-B12 SWMPDSKVFASH 0.38360.394 *
2 3-2-D10 WETDQKFKQRVA 0.34260.347 3-2-D10
2 3-2-D11 WETDQKFKQRVA na /
2 3-2-F6 SAYDDVKRFYTN 0.30760.683 /
3 3-3-F6 ETDNMKPLHLRQ 0.64861.001 3-3-F6
3 3-3-E3 VNDASKLFYPRS 0.38660.510 3-3-E3
3 3-3-H3(1) WPTSWHMWLANR 0.16160.146 /
3 3-3-A7 GVPDNHKPARTQ 0.13160.121 /
3 3-3-A2 ALPTHMNWVMPV 0.11360.074 /
3 3-3-A4 TWPQWWWTNSKG 0.11160.071 /
3 3-3-B8 NPPIWGTATKGI 0.09160.058 /
3 3-3-E8 FWKPHRTHFWWG 0.08060.046 /
3 3-3-H3(2) YNWETDKPMPVP 0.05160.034 /
3 3-3-A3 TWWWHSLAKTPH 0.03660.020 /
3 3-3-C12 TTWNFKHWWPYR 0.02160.018 /
3-3-H3(1) and 3-3-H3(2) are two different phage clones, na: not applicable, SD: standard deviation,
*not withheld: similar to 3-2-G5 & 3-2-G10.
The phage clones were selected after two or three positive (pos) selections. The peptide sequences that were expressed by these phage clones are given in column
three. The average ODc in sandwich ELISA, using nine purified antibody fractions as capture antibody, is shown in column four. If the peptide sequence was synthesised,
the name of the biotinylated peptide is given in column five.
doi:10.1371/journal.pntd.0001682.t001
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1.3 sequence (7/16 AA, 44%). The reverse sequence of the peptides
displayed by phage clones 3-2-C5 and 3-3-E3 showed respectively
31 and13%identity withinAA180to 196(alignment 2).Withinthe
C-terminal domain (alignment 3), the peptide expressed by phage
clone 3-2-C5 and 3-3-E3 had 25% identity (4/16 AA) within AA
404 to 443 of VSG LiTat 1.3. The peptide expressed by phage
clones 3-2-G10, 3-2-G5 and 3-2-B12 were respectively 31%, 19%
and 19% identical within AA 404 to 443 of VSG LiTat 1.3.
All selected phage clones were tested in a sandwich ELISA with
the individual purified antibody fractions. The peptides displayed
by the seven phage clones with the highest average ODc were
withheld for synthesis as biotinylated peptides (table 1). The
peptide displayed by phage clone 3-2-B12 was not withheld, since
it was a homologue of 3-2-G10 and 3-2-G5 but had a lower
average ODc. Based on the alignment results, AA stretch 78 to 110
and AA stretch 424 to 439 of the protein sequence of VSG LiTat
1.3 were also synthesised as biotinylated peptides (respectively
peptide 1.3/78-110 and peptide 1.3/424-439).
The reactivity of all nine biotinylated synthetic peptides was
evaluated in indirect ELISA with the nine HAT positive sera used
for affinity antibody purification, and with nine endemic negative
controls. Peptide 1.3/78-110 was the best performing peptide with
ODc 1.469. Peptide 1.3/424-439 gave a lower average ODc
(0.246) than peptides 3-2-G10 and 3-2-G5 (0.564 and 0.920),
sharing the same common motive, and was not withheld for
further testing. Peptide 3-2-E2, a homologue of peptide 3-2-D10,
also gave a lower average ODc (0.541 versus 0.763) and was also
not withheld for testing on diagnostic performance.
Selection of mimotopes for VSG LiTat 1.5
During the selection process, one of 94 phage clones of the first
positive selection, two of 94 phage clones of the second positive
selection and 20 of 188 phage clones of the third positive selection
reacted in the sandwich ELISA and were sequenced, resulting in
20 sequences (table 2).
The alignment results of VSG LiTat 1.5 [GenBank HQ662603]
and the 20 peptide sequences displayed by the phage clones are
presented in figure 2.
The peptide expressed by phage clone 5-1-F9 (19% identity)
could be aligned within AA 33 to 47 (alignment 1).
Within the N-terminal domain, 18 phage peptides could be
aligned with minimum 6% identity within AA 81 to 119 (alignment
2), by analogy with alignment 1 for VSG LiTat 1.3. The peptides
expressed by clones 5-3-C7, 5-3-A8 and 5-3-B5 respectively had 0, 0
and 6% identity within this AA stretch, but shared the common
motive (W/F)Y with the peptide expressed by phage 5-3-B8 (19%
identity). Thepeptide of phage clone5-3-G6hadonly1/16 AA (6%)
identity with VSG LiTat 1.5 but two more AA were homologous
within this region. The reverse sequences of phage clone peptides 5-
3-F7(13%identity), 5-1-F9 (19%identity) and5-3-D5 (13%identity)
could also be aligned within this VSG LiTat 1.5 region. The peptide
expressed by clone 5-3-B9 had the highest identity within the AA 81
to 119 stretch (5/16 AA, 31% identity, if a gap of 1 AA was allowed).
Peptides expressed by phage clones 5-3-C1, 5-3-A4 and 5-3-A6,
with common motive ‘‘KLANP’’, could also be aligned between
AA 145 to 166 of the VSG LiTat 1.5 protein sequence (alignment
3) with respectively 25, 13 and 13% identity. Within the VSG
LiTat 1.5 AA stretch 245 to 281, the peptide expressed by phage
clone 5-3-A6, showed 19% identity and the reverse peptide
sequence of phages 5-3-B9, 5-3-A3 and 5-3-A4 showed respec-
tively 19, 19 and 13% identity (alignment 4). Within the boundary
with the C-terminal domain of VSG LiTat 1.5, showed the
peptides expressed by phage clones 5-3-A8, 5-3-C1 and 5-3-B6
respectively 19, 31 and 31% identity within AA stretch 341 to 368,
if a gap of three AA was allowed for peptide 5-3-C1 (alignment 5).
Within the C-terminal domain of VSG LiTat 1.5, phage clone
peptide 5-3-B9 and 5-3-A4 had respectively 31 and 13% identity
between AA 468 to 489 (alignment 6).
Figure 1. Alignment on VSG LiTat 1.3 of peptides selected with anti-VSG LiTat 1.3 antibody fractions. Homologous sequences between
phage displayed peptides and/or the protein sequence of VSG LiTat 1.3 are indicated in grey. Amino acids that are identical to those of the VSG
protein sequence are in bold and grey. All peptide sequences include the GGGS-spacer at the C-terminus. Maximum % identity: percentage identity
of the peptide sequence with a corresponding stretch of sixteen AA within the protein sequence of VSG LiTat 1.3. Synth peptide: name of the
synthesised peptide.
doi:10.1371/journal.pntd.0001682.g001
Peptide Mimotopes for T.b.gambiense VSG
www.plosntds.org 5 June 2012 | Volume 6 | Issue 6 | e1682All selected phage clones were tested in a sandwich ELISA with
the individual purified antibody fractions (table 2). The peptides
displayed by the seven phage clones with the highest average ODc,
were chosen for synthesis as biotinylated peptides, except for the
peptide displayed by phage clone 5-3-A6, which was similar to 5-
3-C1 but had a lower average ODc. Based on the alignment results
and by analogy with VSG LiTat 1.3, the AA stretch 81 to 109 of
the protein sequence of VSG LiTat 1.5 was synthesised as
biotinylated peptide (peptide 1.5/81-109).
The reactivity of all eight biotinylated synthetic peptides was
evaluated in indirect ELISA with the nine sera used for affinity
antibody purification and with nine endemic negative controls.
Peptide 5-3-A4 and 5-3-G6 had the lowest average ODcs (0.145
and 0.109) and shared a common motive with peptide 5-3-C1 with
a higher average ODc (0.289) and were therefore not withheld for
testing on diagnostic performance. Peptide 1.5/81-109 had an
ODc of 0.382 and was withheld.
Assessment of the performance of the biotinylated
peptides for diagnosis of gambiense HAT
The accuracy of the biotinylated peptides to detect VSG-specific
antibodies was assessed with sera from 102 gambiense HAT patients
and 102 endemic negative controls (table 3). Among the
mimotopes for VSG LiTat 1.3, the highest AUC was obtained
with peptide 3-2-G5 (0.93) and peptide 3-2-G10 (0.95). Sensitiv-
ities and specificities at the cut-off with the highest Youden index
were respectively 0.85 and 0.94 for peptide 3-2-G5, and 0.90 and
0.93 for peptide 3-2-G10. Of the mimotopes for VSG LiTat 1.5
the highest AUC was obtained with peptide 5-1-F9 (0.95) and 5-2-
D3 (0.94) with respective sensitivities and specificities of 0.94 and
0.95 for peptide 5-1-F9 and 0.92 and 0.89 for peptide 5-2-D3.
With peptide 1.3/78-110, an AUC of 0.95 was observed, with a
sensitivity of 0.96 and a specificity of 0.85. With peptide 1.5/81-
109, an AUC of 0.79, a sensitivity of 0.81 and a specificity of 0.75
were obtained.
VSG LiTat 1.3 and 1.5 obtained an area under the curve of
respectively 1.000 and 0.997. The sensitivity and specificity were
both 1.000 at cut-off 1.318 for VSG LiTat 1.3 and 1.000 and
0.990 at cut-off 1.182 for VSG LiTat 1.5.
Three dimensional epitope mapping of the peptides with
diagnostic potential
By using 3DEX software and setting the number of hits at a
minimum of 5 AA, none of the VSG LiTat 1.3 mimotopes with
AUC.0.90 could be mapped as a conformational epitope on the
protein model of the VSG LiTat 1.3. In contrast, among the VSG
Table 2. Peptide sequences of phage clones selected with human anti VSG LiTat 1.5 antibodies.
Positive selection Phage clone Peptide sequence ODc (average ± SD) Synthetic peptide
1 5-1-F9 AAIMHQEQESNT 0.40360.693 5-1-F9
2 5-2-D3 SAGFENDGTKLA 0.24660.120 5-2-D3
2 5-2-H2 TGLPTTNKQTSS 0.23460.196 5-2-H2
3 5-3-C1 AYSKPTIKLANP 0.49660.758 5-3-C1
3 5-3-E8 AYSKPTIKLANP na /
3 5-3-C5 AYSKPTIKLANP na /
3 5-3-B9 LPLATADKNGRT 0.43660.624 5-3-B9
3 5-3-A4 DKLDNPGGPTVG 0.29160.404 5-3-A4
3 5-3-E5 DKLDNPGGPTVG na /
3 5-3-A6 LQMPHNSKTANP 0.26160.423 *
3 5-3-G6 INGQFSLKYRNP 0.25360.188 5-3-G6
3 5-3-D4 LMPNKISNFASA 0.20960.144 /
3 5-3-A1 DQTCNSPPCPPL 0.18660.156 /
3 5-3-F7 STLPPPQGKIIH 0.18560.243 /
3 5-3-B8 WYPLHSGLRSYY 0.15660.121 /
3 5-3-B6 NKSTTNDFLRSP 0.14160.122 /
3 5-3-D6 NGDYLQYKAPNP 0.13960.141 /
3 5-3-B5 NTVRPPTLFYHW 0.12660.109 /
3 5-3-D5 WHSEYQEPYPLS 0.12060.103 /
3 5-3-A3 LDKNVLSPPMPL 0.10760.082 /
3 5-3-C7 HHMSWYSRWLPV 0.09160.071 /
3 5-3-A8 WWKPWSNFYGST 0.08560.060 /
3 5-3-B3 LNTQNHAPLPSI 0.08060.057 /
na: not applicable, SD: standard deviation,
*not withheld: similar to 5-3-C1.
The phage clones were selected after 1, 2 or 3 positive selections. The peptide sequences that were expressed by these phage clones are given in column three. The
average ODc in sandwich ELISA, using nine purified antibody fractions as capture antibody, is shown in column four. If the peptide sequence was synthesised, the name
of the biotinylated peptide is given in column five.
doi:10.1371/journal.pntd.0001682.t002
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mapped with 8/12 AA (E 168|N 164|D 152|G 153|T 150|K
146|L 144|A 141) on the three-dimensional VSG LiTat 1.5
protein model (figure 3).
Discussion
In this manuscript we describe how mimotopes and regions that
take part in epitope formation for VSGs LiTat 1.3 and LiTat 1.5
of T.b. gambiense were identified by screening of a Ph.D.-12 phage
display library with polyclonal antibodies that were purified from
sera of sleeping sickness patients.
As sera from sleeping sickness patients contain an important
fraction of trypanosome unrelated antibodies [31], the risk of
selecting mimotopes that are unrelated to sleeping sickness by
using human sera for the screening was considerable.
We identified a linear region between amino acid 72 and 114 of
the protein sequence of both VSG LiTat 1.3 and LiTat 1.5
wherein most of the peptide sequences could be aligned with the
VSG protein sequence. This region is localised in the hypervari-
able N-terminal domain of the VSG and was for both VSGs
synthesised as a linear biotinylated peptide and tested in indirect
ELISA with a panel of 102 HAT positive and 102 endemic
negative sera.
Peptide 1.3/78-110, corresponding to AA stretch 78 to 110 of
VSG LiTat 1.3, had an AUC of 0.95, indicating diagnostic
potential. The epitope of VSG LiTat 1.3, recognised by the
human serum antibodies used for screening of the peptide library,
therefore seems to be linear and located within AA stretch 78 to
110. The peptide sequences that were selected for VSG LiTat 1.3
had in average 3/16 amino acids in common within AA 72 to 114
with a maximum of 7/16 (44%) identical amino acids. Interest-
ingly, a common motive of the peptide sequences was repeated
twice within AA 72 to 114 of VSG LiTat 1.3: (F/W)ExDxK(A/L/
V)x(A/L/V), from AA 77 to 85 and 101 to 109.
The two mimotopes of VSG LiTat 1.3 with the highest AUC,
peptide 3-2-G5 and 3-2-G10, seemed to share a common epitope
(correlation coefficient of ODcs with human sera in ELISA 0.71,
data not shown), their motive WxxDxK reoccurred twice within
AA 72 to 114. Their motive, (I/V/A)(T/S)DSK, could also be
aligned within the C-terminal domain (AA 424 to 439). This AA
stretch was synthesised as a biotinylated peptide as well, but had a
Figure 2. Alignment on VSG LiTat 1.5 of peptides selected with anti-VSG LiTat 1.5 antibody fractions. Homologous sequences between
phage displayed peptides and/or the protein sequence of VSG LiTat 1.5 are indicated in grey. Amino acids that are identical to those of the VSG
protein sequence are in bold and grey. All peptide sequences include the GGGS-spacer at the C-terminus. Maximum % identity: percentage identity
of the peptide sequence with a corresponding stretch of sixteen AA within the protein sequence of VSG LiTat 1.5. Synth peptide: name of the
synthesised peptide.
doi:10.1371/journal.pntd.0001682.g002
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was discarded for further evaluation of diagnostic performance.
We think it unlikely that peptide 3-2-G5 and 3-2-G10 are
mimotopes for a linear epitope localised in the C-terminal domain
of VSG LiTat 1.3. Additionally, epitopes localised in the relatively
conserved C-terminal domain are more likely to react with non-
VSG-specific antibodies.
As for VSG LiTat 1.3, a repetitive motive was present within
AA 81 to 114 of VSG LiTat 1.5: (Y/F/W)(x or xx)(A/L/I/V)A(A/
I/L)(D or K) (A/L)xxxxE, from AA 83 to 94 and AA 99 to 111.
The peptide sequences selected for VSG LiTat 1.5 had in average
2/16 AA in common within AA 82 to 114 of the protein sequence,
with a maximum of 5/16 (31%) identical AA. Contrary to the
results for peptide 1.3/78-110, peptide 1.5/81-109, corresponding
to AA stretch 81 to 109 of VSG LiTat 1.5, had an AUC of only
0.79, while the AUC of all of the individual peptides aligned in this
region was .0.85. Motive AYSxxxIKL of peptide 5-3-C1 (AUC
0.87), corresponded to LYSxxxAKL (AA 99 to 106) of the VSG
LiTat 1.5 protein sequence. Peptide 5-3-C1 seems therefore to
mimic an epitope that is, albeit partly, localised in this region. The
similar peptide 5-2-D3, with motive F(x)xxxxKL, performed better
in ELISA (AUC 0.94). It is possible that peptide 5-2-D3 and 5-3-
C1 are mimotopes for a discontinuous epitope as they share the
common motive (A/I/L) (Y/F) xxxxxKLANPG with four other
peptides, while ANPG was not found in the VSG protein
sequence. We therefore suspect the epitope of VSG LiTat 1.5,
recognised by the human serum antibodies used for screening, to
be discontinuous and to be at least partly localised within this
region. This might explain the weaker performance of the linear
peptide 1.5/81-109 compared to the mimotope peptides. This
finding was supported by the results of the 3DEX analysis of the
mimotopes that had an AUC.90, locating peptide 5-2-D3 with
8/12 AA on the three-dimensional VSG LiTat 1.5 protein model
(E 168|N 164|D 152|G 153|T 150|K 146|L 144|A 141).
In a previous study [16] we were able to identify mimotope
peptides for the native trypanosomal variant surface glycoproteins
by screening of peptide phage display libraries with monoclonal
antibodies. Through phage display with polyclonal human
antibodies we now identified different mimotopes and regions
taking part in epitope formation. Because the three monoclonal
antibodies used in the first study represent only a fraction of the
VSG-specific antibody response, some mimotopes with diagnostic
potential might have been missed. Additionally, the mouse and
human immune system may recognise different B cell epitopes.
Other factors may have contributed to finding different motives
using the two approaches. As a result of a short infection period of
two weeks, the mouse monoclonals do not recognise all VSG-
epitopes. They were selected for strict VAT-specificity with
purified VSGs and identified mimotopes, not necessarily domi-
nant, that were located near the surface of the VSG N-terminal
domain. The polyclonal human antibodies result from a long
infection and recognise also less exposed VSG-epitopes. It may be
that by affinity purification on purified VSG an antibody fraction
that recognises non-surface epitopes was mainly retained, as the
mimotopes of VSG LiTat 1.3 seem to be located in this region.
Another explanation may lie in the presence of self-reactive VSG-
specific antibodies in sera from uninfected individuals, as has been
demonstrated by Mu ¨ller et al. [32]. Thus the negative selection
with human antibodies from control sera may have eliminated the
phages expressing the mimotopes for the VSG-specific epitopes
also recognised by the mAbs. Both panning strategies thus seem
complementary, in contrast to what has been described by Tang
et al. [18], who selected a greater number of different 12-mer
sequences with polyclonal serum for Salmonella enterica, but some of
the common motives were also selected by panning of a
monoclonal antibody. In the manuscript of Casey et al. [17] the
mimotopes for Epstein-Barr (EBV) virus, selected with polyclonal
EBV immune rabbit and patient sera were also not recognised by
the monoclonal antibodies used for mimotope selection in a
previous study.
Diagnostic evaluation of individual mimotopes and combina-
tions [patent application GB1202460.0] indicates that screening of
Table 3. Evaluation of the potential of the biotinylated peptides for diagnosis of T.b. gambiense HAT.
Antigen type Name AUC (95% CI) sensitivity (95% CI) specificity (95% CI)
LiTat 1.3 1.3/78-110 0.95 (0.91–0.98) 0.96 (0.90–0.99) 0.85 (0.77–0.92)
LiTat 1.3 3-2-G10 0.95 (0.91–0.97) 0.90 (0.83–0.95) 0.93 (0.86–0.97)
LiTat 1.3 3-2-G5 0.93 (0.89–0.96) 0.85 (0.77–0.92) 0.94 (0.88–0.98)
LiTat 1.3 3-3-E3 0.89 (0.84–0.93) 0.96 (0.90–0.99) 0.76 (0.67–0.84)
LiTat 1.3 3-3-F6 0.89 (0.84–0.93) 0.82 (0.74–0.89) 0.86 (0.78–0.92)
LiTat 1.3 3-2-C5 0.89 (0.84–0.93) 0.90 (0.83–0.95) 0.82 (0.74–0.89)
LiTat 1.3 3-2-D10 0.86 (0.81–0.91) 0.86 (0.78–0.92) 0.81 (0.72–0.88)
LiTat 1.5 5-1-F9 0.95 (0.91–0.97) 0.94 (0.88–0.98) 0.95 (0.89–0.98)
LiTat 1.5 5-2-D3 0.94 (0.90–0.97) 0.92 (0.85–0.97) 0.89 (0.82–0.94)
LiTat 1.5 5-2-H2 0.88 (0.82–0.92) 0.82 (0.74–0.89) 0.81 (0.72–0.88)
LiTat 1.5 5-3-C1 0.87 (0.82–0.92) 0.86 (0.78–0.92) 0.79 (0.70–0.87)
LiTat 1.5 5-3-B9 0.85 (0.79–0.89) 0.79 (0.70–0.87) 0.83 (0.75–0.90)
LiTat 1.5 1.5/81-109 0.79 (0.73–0.85) 0.81 (0.72–0.88) 0.75 (0.65–0.83)
Native VSG LiTat 1.3 1.000 (0.982–1.000) 1.000 (0.964–1.000) 1.000 (0.964–1.000)
Native VSG LiTat 1.5 0.997 (0.973–1.000) 1.000 (0.964–1.000) 0.990 (0.947–1.000)
The ability of biotinylated synthetic peptides to bind human serum antibodies in 102 HAT positive and 102 endemic negative control sera was assessed by indirect
ELISA. The area under the receiver operator characteristics curve (AUC) and the sensitivity and specificity at maximum Youden index are shown with 95% confidence
intervals (CI).
doi:10.1371/journal.pntd.0001682.t003
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www.plosntds.org 9 June 2012 | Volume 6 | Issue 6 | e1682peptide phage display libraries with patient’s antibodies resulted in
a more efficient selection of diagnostic peptides than with
monoclonal antibodies. We therefore prefer screening with
patient’s antibodies. As an alternative approach to phage display
linear epitopes may be replaced by synthetic peptides identified by
scanning of overlapping peptides spanning the native protein
sequence [33]. Furthermore, there are alternative in vitro methods
for phage display such as yeast cell or bacterial display or, non-
cellular, ribosome or mRNA display [34].
Our study has nevertheless some limitations. First, considering
the broad antibody spectrum in HAT sera due to polyclonal B cell
activation [35], we opted to use antibody fractions that were
affinity purified for VSG LiTat 1.3 and 1.5. Thus, mimotopes for
other predominant VSGs or other trypanosome antigens with
diagnostic potential have not been selected. An alternative
approach to identify additional diagnostic mimotopes may consist
of screening peptide phage libraries with patient antibodies against
other candidate diagnostic proteins [36]. Examples are the T.b.
gambiense-specific glycoprotein TgsGP [37], the T.b. rhodesiense-
specific serum resistance associated (SRA) protein [38] and
Trypanozoon-specific trypanosome antigens such as invariant
surface glycoprotein (ISG) 65 and ISG 75 [39], microtubule
associated repetitive protein 1 (MARP1) and GM6 [40]. Some of
them have already been tested for their diagnostic potential in the
form of recombinant fusion proteins expressed in E. coli but none
are yet used in diagnostic tests for HAT. Second, even with affinity
purified antibodies there is a risk that non-specific mimotopes are
selected with antibodies against VSG epitopes that are normally
hidden in the intact VSG coat. Usually, most of the phage particles
display a consensus binding sequence after two or three rounds of
enrichment [21]. We therefore performed three rounds of positive
selection and two selections with negative sera. Remarkably, the
mimotopes with the highest AUC for VSG LiTat 1.3 and 1.5 were
selected after only two or even one round of panning. Third, no
affinity measurements e.g. via surface plasmon resonance, have
been performed. Considering the polyclonal character of antibod-
ies in patients’ sera and the inherent differences in antibody
response between individual patients, we opted to assess only the
diagnostic potential of the selected peptides by means of ELISA.
Before the native T.b. gambiense VSGs LiTat 1.3 and LiTat 1.5 in
the currently existing diagnostic formats can be replaced by
synthetic peptides, further improvements should be considered. It
is possible to define critical residues, essential for binding with the
antibody, by e.g. alanine scanning mutagenesis [41]. Thus the
epitope of the human serum antibodies might be recreated as has
recently been done for a linear epitope on the VP1 protein of foot-
and mouth disease virus [42]. Other, non-essential, parts of the
peptides can then be eliminated in order to increase specificity.
Phage clones that express peptides with a higher binding affinity
might be selected by increasing the number of selection rounds
and/or the stringency of the washing steps.
In conclusion, with this study we demonstrate that mimotopes of
T.b. gambiense VSG LiTat 1.3 and 1.5 can be selected from a phage
display library and that these mimotopes and corresponding
amino acid stretches within the VSGs have diagnostic potential.
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